cantharidin · Verrica Pharms · NDA 212905
Ycanth
Earliest generic entry, as listed
19 Feb 2041
Blocked by patent: US 12290651.
Listed patents · 4 unexpired
6 Orange Book listing rows for 4 patents. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.
| Patent | Claims | Expires |
|---|---|---|
| US 12290651 | drug product · sets the listed date | 19 Feb 2041 |
| US 11147790 | drug product, use U-3663, U-3664 | 22 Aug 2038 |
| US 11147790 listing row | drug product, use U-3663 | 22 Aug 2038 |
| US 11147790 listing row | drug product, use U-3664 | 22 Aug 2038 |
| US 12233042 | drug product, use U-3663 | 22 Aug 2038 |
| US 11052064 | drug product, use U-3663, U-3665 | 28 May 2035 |
| US 11052064 listing row | drug product, use U-3663 | 28 May 2035 |
| US 11052064 listing row | drug product, use U-3665 | 28 May 2035 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 21 Jul 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 212905 · 001 · RLD | solution, topical | 0.7% | 19 Feb 2041 |